AQST
NASDAQ · Pharmaceuticals
Aquestive Therapeutics Inc
$3.98
-0.08 (-1.97%)
Financial Highlights (FY 2026)
Revenue
83.52M
Net Income
-64,041,713
Gross Margin
68.9%
Profit Margin
-76.7%
Rev Growth
+4.2%
D/E Ratio
4.68
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 68.9% | 68.9% | 55.1% | 55.1% |
| Operating Margin | -53.5% | -48.1% | 28.0% | 27.5% |
| Profit Margin | -76.7% | -72.9% | 25.7% | 25.5% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 83.52M | 80.13M | 128.94M | 106.66M |
| Gross Profit | 57.59M | 55.25M | 71.02M | 58.74M |
| Operating Income | -44,651,007 | -38,555,028 | 36.05M | 29.37M |
| Net Income | -64,041,713 | -55,298,418 | 33.13M | 27.21M |
| Gross Margin | 68.9% | 68.9% | 55.1% | 55.1% |
| Operating Margin | -53.5% | -48.1% | 28.0% | 27.5% |
| Profit Margin | -76.7% | -72.9% | 25.7% | 25.5% |
| Rev Growth | +4.2% | +4.2% | +19.1% | -7.7% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 214.14M | 214.14M | 204.59M | 185.15M |
| Total Equity | 45.73M | 45.73M | 356.51M | 373.84M |
| D/E Ratio | 4.68 | 4.68 | 0.57 | 0.50 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -51,532,878 | -46,969,427 | 53.66M | 42.58M |
| Free Cash Flow | — | — | 23.71M | 15.65M |